| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -870 | -960 | -1,710 | -1,460 | -970 |
| Net Income Growth | +9.37% | +43.86% | -17.12% | -50.52% | +31.69% |
Decoy Therapeutics Inc
(DCOY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Decoy Therapeutics Inc. is a preclinical-stage biotechnology company which target serious unmet medical needs. The Company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy Therapeutics Inc., formerly known as Salarius Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31